Showing results (1-10 of 108) with videos related to

Sort By:
Pageof 11
Cardiovascular Drugs and Therapy|May 25, 2023
Rivaroxaban in Valvular Atrial Fibrillation - a Critical Appraisal of the INVICTUS TrialAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
Cardiovascular Drugs and Therapy|June 14, 2022
Rivaroxaban After Transcatheter Aortic Valve Replacement: A Critical Appraisal of the GALILEO TrialPatrick Sulzgruber, Andreas Hammer, Alexander Niessner
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|September 18, 2021
The impact of CD4+CD28null T lymphocytes on atrial fibrillation: a potential pathophysiological pathwayAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
Cardiovascular Drugs and Therapy|October 12, 2023
Early Initiation of SGLT2 Inhibitors in Acute Heart Failure: a Focus on Diuresis and Renal ProtectionAndreas Hammer, Alexander Niessner, Patrick Sulzgruber
European Heart Journal. Case Reports|November 18, 2020
The personalized antithrombotic management of atrial fibrillation with intermediate thromboembolic risk: a case reportAndreas Hammer, Sebastian Schnaubelt, Alexander Niessner, et al.
Studies in Health Technology and Informatics|January 25, 2024
Development of Cross-Sector Health Care Quality Indicators Based on Claims DataWalter Gall, Hana Šinkovec, Alexander Niessner, et al.
Heart Failure Reviews|June 5, 2018
Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysisMax-Paul Winter, Patrick Sulzgruber, Lorenz Koller, et al.
Resuscitation Plus|August 28, 2023
Out of sight - Out of mind? The need for a professional and standardized peri-mission first responder support modelSebastian Schnaubelt, Simon Orlob, Christoph Veigl, et al.
Thrombosis and Haemostasis|December 18, 2020
The Age-Specific Impact of Cellular Immunity on Long-Term Outcome after Acute Coronary SyndromeNiema Kazem, Felix Hofer, Lorenz Koller, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|April 15, 2020
Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategiesFelix Hofer, Niema Kazem, Andreas Hammer, et al.
Pageof 11